Early Access to CleanPlex Respiratory Research Panel Combining Influenza A/B and SARS-CoV-2 Testing
Paragon Genomics released CleanPlex® SARS-CoV-2 Research and Surveillance Panel a few months ago for ultra-sensitive detection and complete genomic sequencing of the SARS-CoV-2 virus responsible for COVID-19 pandemic. As the flu season nears, there is a need for assaying SARS-CoV-2 and influenza viruses concurrently. The CleanPlex® Respiratory Research Panel combines the original SARS-CoV-2 whole genome sequencing with expertly selected primers specific to influenza A subtypes H1N1, H1N2, H3N2, and influenza B. The panel contains over 80 strategically selected targets to cover characteristic regions of each viral segment for highly confident detection and identification. The NGS panel not only allows detection and differentiation of the two viruses but also enables subtyping and strain information for mutation analysis, tracking, surveillance, and informed infection control through comprehensive sequence information. Compared to most qPCR-based methods, this NGS-based panel covers many more targets and is suitable for higher throughput sample pooling on Illumina and MGI sequencers.
Dr. Xiaowu Gai, Director of Bioinformatics at the Center for Personalized Medicine in the Department of Pathology and Laboratory Medicine at Children’s Hospital Los Angeles, and Associate Professor of Clinical Pathology at the Keck School of Medicine at the University of Southern California, said, “I was very impressed by how well the CleanPlex SARS-CoV-2 panel worked when we evaluated it back in March. Working with Paragon Genomics, we were able to leverage the panel to quickly launch a SARS-CoV-2 whole-genome sequencing assay and used it effectively for a number of genomic epidemiology studies. “
To request early access to the CleanPlex® Respiratory Research Panel, please fill out the form below.